墨西哥引入PCV13后儿童侵袭性与非侵袭性肺炎球菌疾病血清型分布(2012—2023年):GIVEBPVac研究组结果
该研究收集2012年1月至2023年12月墨西哥参与医院住院儿童的肺炎球菌分离株,分析<5岁和≥5~17.9岁儿童的血清型分布及趋势。结果显示19A是最常见的PCV13血清型,3和19F次之;PCV13覆盖血清型(除3、19A、19F外)在两个年龄组均下降,≥5~17.9岁组非PCV13血清型显著增加。作者认为持续监测对识别新出现血清型和选择合适疫苗至关重要。
要点
- 19A是<5岁和≥5~17.9岁儿童中最常见的PCV13血清型,3和19F次之。
- PCV13覆盖血清型(除3、19A、19F外)在<5岁组(p=0.04)和≥5~17.9岁组(p=0.002)均下降。
- ≥5~17.9岁组非PCV13血清型显著增加(p=0.023),17F和34在两个年龄组均增加。
核心结论
- 引入PCV13十年后,13种疫苗血清型中有10种在过去六年未检出,但3、19A和19F仍以高频率持续引起儿童侵袭性和非侵袭性肺炎球菌疾病。
- 作者认为持续有力的监测对识别新出现肺炎球菌血清型、为各国选择合适疫苗及开发下一代疫苗配方至关重要。
研究设计与样本
- 研究收集2012年1月至2023年12月墨西哥参与医院住院儿童的肺炎球菌分离株,分析<5岁和≥5~17.9岁儿童的血清型分布。
- 计算血清型比例的年平均变化(AAC),并使用Cochran-Armitage检验分析趋势。
主要发现
- 19A是<5岁和≥5~17.9岁两个年龄组中最常见的PCV13血清型,其次是3和19F。
- PCV15和PCV20包含的血清型33F在≥5~17.9岁儿童中未检出。
- PCV20血清型中15B最常见,PCV24覆盖的17F在≥5~17.9岁组显著增加(p=0.037)。
- 除17F和34在两个年龄组均增加外,未发现其他单个血清型显著增加或减少的趋势。
- PCV13覆盖血清型(除3、19A、19F外)在<5岁组(p=0.04)和≥5~17.9岁组(p=0.002)均下降;非PCV13血清型在≥5~17.9岁组显著增加(p=0.023)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The introduction of pneumococcal conjugate vaccines (PCVs) since 2000 has altered the epidemiology of invasive (IPD) and non-invasive pneumococcal diseases (NIPD). This study aims to analyze trends in pneumococcal serotype distribution among children in Mexico, focusing on the period following the introduction of PCV13, and assess the potential impact of future vaccines. MATERIAL AND METHODS: Pneumococcal isolates were collected from hospitalized children in participating hospitals from January 2012 to December 2023. Serotype distribution was analyzed in children under <5 years and those aged ≥5 to 17.9 years. The average annual change (AAC) in serotype proportions was calculated, and trends were analyzed using the Cochran-Armitage test. RESULTS: Serotype 19A was the most frequent PCV13 serotype, followed by serotypes 3 and 19F, in both age groups. Serotype 33F, included in PCV15 and PCV20, was absent in children aged ≥5-17.9 years. Among PCV20 serotypes, serotype 15B was the most common, and serotype 17F, covered by PCV24, showed a significant increase in the older age group (p = 0.037). No significant trends in the increase or decrease of individual serotypes were found, except for serotypes 17F and serotype 34, which increased in both age groups. A decrease in serotypes covered by PCV13 (excluding serotypes 3, 19A, and 19F) was observed in both age groups (p = 0.04, 0.002). A significant increase in non-PCV13 serotypes occurred in children aged ≥5-17.9 years (p = 0.023). CONCLUSIONS: After a decade of the introduction of PCV13 in Mexico, 10 of the 13 vaccine serotypes have not been detected in the past six years. However, serotypes 3, 19A, and 19F persist at high frequencies as causes of IPD and NIPD in children. Ongoing robust surveillance is critical for identifying emerging pneumococcal serotypes, selecting appropriate vaccines for each country, and developing next-generation vaccine formulations.
引用
- Soto-Noguerón A, Carnalla-Barajas MN, Sánchez-González G, et al. Distribution of pneumococcal serotypes causing invasive and non-invasive diseases in children in Mexico after introduction of PCV13 (2012-2023). Results from the GIVEBPVac group. Vaccine. 2025. PMID: 40154239. doi:10.1016/j.vaccine.2025.127031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。